Royal Bank of Canada Raises Incyte (NASDAQ:INCY) Price Target to $65.00

Incyte (NASDAQ:INCY – Free Report) had its price objective lifted by Royal Bank of Canada from $63.00 to $65.00 in a research report report published on Wednesday, Benzinga reports. Royal Bank of Canada currently has a sector perform rating on the biopharmaceutical company’s stock. INCY has been the subject of several other research reports. Morgan […]

Related Keywords

Canada ,United States ,Japan ,Vijayk Iyengar ,William Blair ,Stifel Nicolaus ,Incyte Corporation ,Securities Exchange Commission ,Prospera Financial Services Inc ,Citigroup ,Royal Bank ,A Davidson ,Us Bancorp ,Silverarc Capital Management ,Morgan Stanley ,Free Report ,Truist Financial ,Moderate Buy ,Trading Down ,Get Free Report ,Exchange Commission ,Financial Services Inc ,Capital Management ,Clear Street Markets ,Street Markets ,Incyte Daily ,Incyte ,Nasdaq Incy ,Incy ,Medical ,45337c10 ,Boost Price Target ,Royal Bank Of Canada ,